Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Georg Lübben"'
Autor:
Andreas Pfützner, Alexander Weise, Elisabeth Pfützner-Riehn, Georg Lübben, Michael Morcos, Efstrathios Karagiannis, Matthias Weber, Thomas Forst
Publikováno v:
PPAR Research, Vol 2011 (2011)
Background. This study was performed to investigate the influence of a short-term treatment with pioglitazone versus placebo on inflammatory activation of mononuclear cells (mRNA expression/protein secretion of inflammatory markers). Methods and Resu
Externí odkaz:
https://doaj.org/article/b8e5b104ec6341d68940b92a4001130e
Autor:
M. Borchert, A. Pfützner, Thomas Schöndorf, E. Karagiannis, C. Hohberg, Thomas Forst, Georg Lübben
Publikováno v:
Diabetes, Obesity and Metabolism. 11:464-471
AIM Insulin treatment is considered to be the final option for patients with progressive type 2 diabetes. This study investigated, whether reconverting type 2 patients from insulin treatment to oral treatment using pioglitazone is possible without de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f16061d9b8b89df568e52b1837bf4220
https://doi.org/10.1111/j.1463-1326.2008.00975.x
https://doi.org/10.1111/j.1463-1326.2008.00975.x
Autor:
A. Pfützner, Georg Lübben, B. Wilhelm, E. Karagiannis, Markolf Hanefeld, Peter H. Kann, Thomas Schöndorf, Thomas Forst
Publikováno v:
Hormone and Metabolic Research. 41:202-206
Retinol binding protein 4 (RBP4) has recently been suggested as a good biomarker for insulin resistance and the metabolic syndrome. With this study, we wanted to investigate the effect of pioglitazone (PIO) and simvastatin (SIMVA) on insulin resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88527b2c2563094cc2a7ea65318f7f57
https://doi.org/10.1055/s-0028-1104592
https://doi.org/10.1055/s-0028-1104592
Autor:
Thomas Forst, Jens Pietzsch, Georg Lübben, Andreas Pfützner, E. Karagiannis, Jürgen Müller, Markolf Hanefeld, W. Leonhardt
Publikováno v:
Atherosclerosis 201(2008), 155-162
Background We analyzed the efficacy and possible synergistic actions of pioglitazone and simvastatin monotherapy versus their combination on LDL subfractions from a subpopulation from the PIOSTAT three-arm randomized controlled trial. PPARγ agonists
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c5ba4d838d1220eab2e975b24919dbf
https://doi.org/10.1016/j.atherosclerosis.2008.01.007
https://doi.org/10.1016/j.atherosclerosis.2008.01.007
Autor:
E. Karagiannis, J. Merke, M. Dietlein, C. Hofmann, A. Grünerbel, C. Franzen, R. A. Bierwirth, Georg Lübben
Publikováno v:
Der Diabetologe. 4:542-548
Typ-2-Diabetiker haben ein erhohtes Risiko kardiovaskularer Erkrankungen. Glitazone wie Pioglitazon verbessern nicht nur metabolische Parameter, sondern reduzieren auch die Intima-Media-Dicke (IMT) der A. carotis. Dieser Parameter gilt als Pradiktor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b0eae248a5cc155dedc3c30856549ea
https://doi.org/10.1007/s11428-008-0326-4
https://doi.org/10.1007/s11428-008-0326-4
Autor:
W. Dänschel, Andreas Pfützner, Gerhard Dikta, M. Morcos, Georg Lübben, E. Karagiannis, Thomas Forst, M. Drexler, C. Hohberg, Thomas Schöndorf, M. Borchert
Publikováno v:
Atherosclerosis. 197:311-317
We investigated MMP-9 levels and inflammatory markers during pioglitazone treatment in type 2 diabetic patients with cardiovascular disease. In this randomized multicenter, double blinded, placebo controlled study, 92 type 2 diabetic patients with an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f30351bbea48644c29b81c2767c6e780
https://doi.org/10.1016/j.atherosclerosis.2007.05.006
https://doi.org/10.1016/j.atherosclerosis.2007.05.006
Publikováno v:
Journal of Diabetes Science and Technology. 2:244-249
AIM Pioglitazone is an established peroxisome proliferator-activated receptor gamma agonist for the treatment of insulin resistance in patients with type 2 diabetes mellitus. This analysis of the observational IRIS III study was performed to evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7838c7250351a8427eb2b031488177c9
https://doi.org/10.1177/193229680800200212
https://doi.org/10.1177/193229680800200212
Autor:
F. P. Armbruster, A. Pfützner, T. Forst, Georg Lübben, M. Breidenbach, Thomas Schöndorf, M. Borchert, C. Hohberg
Publikováno v:
Geburtshilfe und Frauenheilkunde. 67:348-351
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88111e313cc20f4dc502293ad7781634
https://doi.org/10.1055/s-2007-965090
https://doi.org/10.1055/s-2007-965090
Autor:
Thomas Forst, Carsta Koehler, E. Karagiannis, Markolf Hanefeld, Georg Lübben, Nikolaus Marx, Marc Weber, C. Hohberg, Werner Baurecht, Andreas Pfützner
Publikováno v:
Metabolism. 56:491-496
We investigated the effect of pioglitazone in comparison with and in combination with simvastatin on insulin resistance, plasma adiponectin, postprandial plasma glucose, insulin, and intact proinsulin levels in a nondiabetic population at cardiovascu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c2f3b7f131655572af552d635b7ce4b
https://doi.org/10.1016/j.metabol.2006.11.007
https://doi.org/10.1016/j.metabol.2006.11.007
Autor:
Ulf Stier, Georg Lübben, Markolf Hanefeld, Werner Baurecht, E. Karagiannis, Nikolaus Marx, Thomas Forst, Andreas Pfützner
Publikováno v:
Journal of the American College of Cardiology. 49:290-297
Objectives The purpose of this study was to test the safety and efficacy of pioglitazone and simvastatin in combination versus each drug individually in non-diabetic subjects with cardiovascular disease (CVD) and elevated high-sensitivity C-reactive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68cd57c8e6aa44f3ac55383a447c6f2d
https://doi.org/10.1016/j.jacc.2006.08.054
https://doi.org/10.1016/j.jacc.2006.08.054